E. Souhami

发表

Impact of disease duration and β‐cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on glucagon‐like peptide‐1 receptor agonist therapy: Exploratory analyses from the LixiLan‐G trial

J. Rosenstock, A. Saremi, L. Blonde, 2020, Diabetes, obesity & metabolism.

Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial

J. Rosenstock, L. Blonde, R. Henry, 2019, Diabetes Care.

Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial

J. Rosenstock, R. Bergenstal, V. Aroda, 2016, Diabetes Care.

Efficacy and safety of the glucagon-like peptide-1 receptor agonist lixisenatide versus the dipeptidyl peptidase-4 inhibitor sitagliptin in young (<50 years) obese patients with type 2 diabetes mellitus☆

L. V. Van Gaal, R. Aronson, Tianyue Zhou, 2014, Journal of clinical & translational endocrinology.

Efficacy and safety of insulin glargine/lixisenatide (iGlarLixi) fixed-ratio combination in older adults with type 2 diabetes.

F. Giorgino, J. Frias, Y. Handelsman, 2019, Journal of diabetes and its complications.

Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial

J. Rosenstock, V. Aroda, R. Perfetti, 2016, Diabetes Care.

Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial

M. Hanefeld, J. Rosenstock, G. Grunberger, 2016, Diabetes Care.

Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed‐ratio combination) vs insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan‐L trial

R. Bergenstal, C. Kapitza, V. Aroda, 2017, Diabetes, obesity & metabolism.

iGlarLixi Reduces Glycated Hemoglobin to a Greater Extent Than Basal Insulin Regardless of Levels at Screening: Post Hoc Analysis of LixiLan-L

K. Jensen, E. Niemoeller, E. Souhami, 2017, Diabetes Therapy.

Impact of dose capping in insulin glargine/lixisenatide fixed-ratio combination trials in patients with type 2 diabetes

J. Frias, R. Belder, W. Schmider, 2019, Current medical research and opinion.

Concomitant iGlarLixi and Sodium-Glucose Co-transporter-2 Inhibitor Therapy in Adults with Type 2 Diabetes: LixiLan-G Trial and Real-World Evidence Results

J. Rosenstock, L. Blonde, F. Giorgino, 2021, Diabetes Therapy.

Efficacy of iGlarLixi in adults with type 2 diabetes inadequately controlled (glycated haemoglobin ≥8%, ≥64 mmol/mol) on two oral antidiabetes drugs: Post hoc analysis of the LixiLan‐O randomized trial

J. Rosenstock, M. Davies, D. Russell-Jones, 2021, Diabetes, obesity & metabolism.

Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study

J. Rosenstock, L. Blonde, S. Del Prato, 2021, Diabetes Care.

Switching to iGlarLixi versus continuation of a daily or weekly glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) in insufficiently controlled type 2 diabetes: A LixiLan‐G trial subgroup analysis by HbA1c and GLP‐1 RA use at screening

J. Rosenstock, L. Blonde, S. Del Prato, 2021, Diabetes, obesity & metabolism.

Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine

J. Rosenstock, M. Riddle, R. Aronson, 2013, Diabetes Care.

Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan‐O trial testing a titratable fixed‐ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents

Lawrence A Leiter, J. Rosenstock, G. Grunberger, 2017, Diabetes, obesity & metabolism.

J. Rosenstock, L. Blonde, F. Giorgino, 2020 .

1139-P: Influence of Screening HbA1c Levels on Glucose Control Achieved when Switching to iGlarLixi in T2D Inadequately Controlled on GLP-1RA and OAD(s)

J. Rosenstock, L. Blonde, R. Henry, 2019, Diabetes.

Ef ﬁ cacy and safety of insulin glargine/lixisenatide (iGlarLixi) ﬁ xed-ratio combination in older adults with type 2 diabetes

F. Giorgino, J. Frias, Y. Handelsman, 2019 .

Comparable efficacy and safety of insulin glulisine and insulin lispro when given as part of a Basal-bolus insulin regimen in a 26-week trial in pediatric patients with type 1 diabetes.

T. Danne, S. Arslanian, A. Philotheou, 2011, Diabetes technology & therapeutics.

Efficacy and safety of insulin glulisine in patients with type 1 diabetes.

M. Dreyer, R. Prager, E. Souhami, 2005, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

Improved glycaemic control and weight benefit with iGlarLixi versus insulin glargine 100 U/mL in Chinese people with type 2 diabetes advancing their therapy from basal insulin plus oral antihyperglycaemic drugs: Results from the LixiLan‐L‐CN randomized controlled trial

Xiaohui Guo, Junqing Zhang, Xiaolin Dong, 2022, Diabetes, obesity & metabolism.

Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan‐O‐AP randomized controlled trial

Ming Liu, Wenying Yang, Qingju Li, 2022, Diabetes, obesity & metabolism.

Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia.

Sandrine Andrieu, Graziano Onder, Shalender Bhasin, 2011, Journal of the American Medical Directors Association.

Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial

M. Hanefeld, J. Rosenstock, S. Heller, 2016, Diabetes Care.

Cost-Effectiveness of iGlarLixi Versus iDegLira in Type 2 Diabetes Mellitus Inadequately Controlled by GLP-1 Receptor Agonists and Oral Antihyperglycemic Therapy

R. McCrimmon, M. Lamotte, E. Lew, 2021, Diabetes Therapy.

Hypoglycaemia events with iGlarLixi versus premix biphasic insulin aspart 30 (BIAsp 30) in people with type 2 diabetes advancing from basal insulin: An analysis of the SoliMix trial

J. Rosenstock, P. Home, F. Giorgino, 2022, Diabetes, obesity & metabolism.

Diurnal glucose exposure profiles of patients treated with lixisenatide before breakfast or the main meal of the day: An analysis using continuous glucose monitoring

R. Bergenstal, M. Powers, B. Ahrén, 2017, Diabetes/metabolism research and reviews.

Equal improvement in glycaemia with lixisenatide given before breakfast or the main meal of the day.

R. Aronson, B. Ahrén, E. Souhami, 2014, Journal of diabetes and its complications.

iGlarLixi provides a higher derived time‐in‐range versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with type 2 diabetes: A post hoc analysis

Xiaohui Guo, Junqing Zhang, Ming Liu, 2023, Diabetes, obesity & metabolism.

combination ) versus insulin glargine and lixisenatide monocomponents Running title : Impact of baseline characteristics on clinical outcomes in the LixiLan-O trial

Lawrence A Leiter, J. Rosenstock, G. Grunberger, 2017 .

Comparison of morphometric assessment of prevalent vertebral deformities in women using different reference data.

P. Delmas, J. Zanchetta, P. Szulc, 2000, Bone.

Erratum. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. Diabetes Care 2016;39:1972–1980

J. Rosenstock, R. Bergenstal, V. Aroda, 2017, Diabetes Care.